美容护理行业周报：24年业绩预告陆续披露，关注业绩兑现能力

Investment Rating - The industry investment rating is "Increase" (maintained) [4] Core Viewpoints - The beauty and personal care industry is expected to see a continued increase in medical beauty penetration rates, with a recommendation to focus on companies such as Juzhi Biotech, Aimeike, Jinbo Biological, Jiangsu Wuzhong, Huadong Medicine, Meili Tianyuan Medical Health, and Langzi Co., Ltd. [9] - The cosmetics channel is experiencing traffic differentiation, with intensified competition among brands. Leading domestic brands are expected to maintain their competitive edge through a combination of brand, channel, product, and operational advantages [9] Summary by Relevant Sections Company Performance - Runben Co., Ltd. is expected to achieve a net profit attributable to shareholders of 300 to 310 million yuan in 2024, representing a year-on-year growth of 32.73% to 37.15%. The fourth quarter net profit is projected to be 39 to 49 million yuan, a year-on-year decrease of 13.33% to an increase of 8.89% [1] - Jiangsu Wuzhong's Aisufi is expected to achieve a net profit of approximately 55 to 80 million yuan in 2024, turning a profit compared to the previous year. The fourth quarter net profit is estimated to be 9.92 to 34.92 million yuan, also indicating a turnaround [1] - Jinbo Biological is projected to achieve a net profit of 719 to 737 million yuan in 2024, with a year-on-year growth of 139.83% to 145.83%. The fourth quarter net profit is expected to be 199 to 217 million yuan, reflecting a year-on-year increase of 84.26% to 100.93% [2] Product Development - Wanmei Biological has invested in Shengzhirunhe, focusing on the research and application of regenerative medical materials, particularly in the medical beauty sector [2] - Huadong Medicine's subsidiary has received approval from the National Medical Products Administration (NMPA) for its high-end hyaluronic acid product MaiLi Extreme, which is designed for facial aesthetic procedures [3]